The first EUP OHAMR Joint Transnational Call for Projects is seeking proposals that develop new treatments, tools, and evidence to combat antimicrobial resistance (AMR). Backed by 37 funding organisations across 28 countries with a budget exceeding €31 million, the call focuses on combination therapies, treatment adherence tools, and One Health AMR transmission pathways. This optimized guide explains eligibility, scope, requirements, key concepts, and how to apply.

EUP OHAMR Joint Transnational Call for Projects: New Treatments and Solutions for Antimicrobial Resistance

Overview

The EUP OHAMR (One Health Antimicrobial Resistance) initiative has launched its first joint transnational call to support innovative research that tackles rising AMR threats. The call prioritises new therapeutic approaches, adherence-enhancing tools, and One Health evidence addressing how antimicrobial use in human, veterinary, and agricultural settings influences resistance transmission.

With a total budget of over €31 million, the call unites 37 funding organisations from 28 countries, enabling large-scale collaboration and harmonised research methodologies.

Why It Matters

Antimicrobial resistance is a global public health crisis that undermines the effectiveness of essential medicines. This call matters because it:

• Accelerates the development of new antimicrobial combinations

• Supports practical tools for responsible antimicrobial use

• Provides evidence for better AMR policy and regulation

• Promotes transnational scientific collaboration

• Strengthens One Health research across human, animal, and environmental interfaces

Key Focus Areas

Proposals must align with one or more of the following research priorities:

Combination Treatments

• Develop novel therapeutic combinations

• Extend the lifespan and efficacy of existing antimicrobials

• Strengthen treatment strategies for multidrug-resistant infections

Treatment Adherence Tools

• Create tools, technologies, or interventions that support patient adherence

• Improve the correct, consistent use of antimicrobials

• Reduce misuse and prevent resistance development

One Health AMR Transmission

• Assess how antimicrobial use in veterinary and agricultural systems affects AMR spread

• Study cross-species and environmental transmission routes

• Provide evidence to inform national and international policy

Core Proposal Requirements

To be competitive, proposals must clearly demonstrate:

• Feasibility and realistic work plans

• Defined objectives, milestones, and timelines

• Expected health, social, and economic impact

• Contributions of each partner and the added value of collaboration

• Alignment with One Health principles

• Scalability and long-term relevance

Expanded Explanation of Key Concepts

One Health

An integrated approach recognizing the interconnection between human health, animal health, and the environment. AMR solutions must work across all three domains.

Antimicrobial Resistance (AMR)

A biological process in which pathogens evolve mechanisms that reduce or eliminate the effectiveness of antimicrobial treatments.

Combination Therapy

The use of two or more drugs together to improve treatment efficacy and slow resistance emergence.

Treatment Adherence

The degree to which patients correctly follow treatment plans, which heavily influences AMR outcomes.

Who Is Eligible?

The call supports transnational research consortia. Requirements include:

• At least one Principal Investigator (PI) per participating institution

• Partners from eligible countries aligned with the funding rules

• Consortia capable of conducting multidisciplinary One Health research

• Organisations able to execute scientific, clinical, veterinary, or environmental AMR studies

Eligible participants may include:

• Universities and research institutions

• Hospitals and clinical centres

• Veterinary and agricultural research organisations

• Public health agencies

• Non-profit research organisations

How the Programme Works

The transnational format ensures:

• Access to shared scientific infrastructure

• Harmonised research methods

• Cross-border knowledge exchange

• Scalability and broader applicability of research outcomes

Each project PI is responsible for their institution’s tasks and research outputs.

How to Apply

Step 1: Review Call Documents

Understand scope, funding rules, eligibility conditions, and national regulations.

Step 2: Build a Transnational Consortium

Identify partners from participating countries. Ensure complementary expertise across One Health domains.

Step 3: Define Research Goals

Prepare a clear, feasible research plan with measurable outcomes and a logical timeline.

Step 4: Develop Work Packages

Assign tasks to each PI, including responsibilities, deliverables, and resource needs.

Step 5: Demonstrate Impact

Highlight expected benefits for public health, animal health, agriculture, regulation, and society.

Step 6: Submit the Proposal

Follow the submission platform instructions and meet all deadlines.

Common Mistakes to Avoid

• Vague or overly broad research aims

• Missing One Health integration

• Weak justification for transnational cooperation

• Poorly defined partner roles

• Lack of measurable impact indicators

• Incomplete budget justification

Frequently Asked Questions (FAQ)

1. What is the main purpose of this transnational call?

To fund research that develops new treatments, tools, and evidence to reduce antimicrobial resistance across One Health systems.

2. How many countries participate?

A total of 28 countries, represented by 37 funding organisations.

3. What types of projects are eligible?

Projects addressing combination therapies, adherence tools, and AMR transmission linked to veterinary and agricultural antimicrobial use.

4. Who can join a consortium?

Research institutions, universities, hospitals, veterinary and agricultural scientists, and other organisations able to contribute scientifically.

5. Are One Health principles mandatory?

Yes, proposals must explicitly consider human, animal, and environmental implications.

6. How many Principal Investigators can each institution have?

One PI per participating institution, each responsible for their assigned tasks.

7. What determines funding success?

Scientific excellence, feasibility, transnational value, One Health alignment, and measurable societal impact.

Conclusion

The first EUP OHAMR Joint Transnational Call offers a major opportunity to advance innovative research addressing antimicrobial resistance through new therapies, adherence solutions, and One Health evidence. With significant funding and broad international collaboration, the call supports impactful projects that can shape future AMR policy, improve treatment outcomes, and protect human, animal, and environmental health. Researchers and institutions committed to combating AMR are strongly encouraged to participate.